Bioelife (LITH) Stock Price
Bioelife Price
The stock trades about 100% above its 52-week low.
Bioelife stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Bioelife over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Bioelife stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Bioelife's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Bioelife Price |
|---|---|
| 8/3/2026 | 0.00 USD |
| 7/30/2026 | 0.00 USD |
| 7/29/2026 | 0.00 USD |
| 7/28/2026 | 0.00 USD |
| 7/27/2026 | 0.00 USD |
| 7/24/2026 | 0.00 USD |
| 7/23/2026 | 0.00 USD |
| 7/22/2026 | 0.00 USD |
| 7/21/2026 | 0.00 USD |
| 7/20/2026 | 0.00 USD |
| 7/17/2026 | 0.00 USD |
| 7/16/2026 | 0.00 USD |
| 7/15/2026 | 0.00 USD |
| 7/14/2026 | 0.00 USD |
| 7/13/2026 | 0.00 USD |
| 7/10/2026 | 0.00 USD |
| 7/9/2026 | 0.00 USD |
| 7/8/2026 | 0.00 USD |
| 7/7/2026 | 0.00 USD |
| 7/6/2026 | 0.00 USD |
| 7/2/2026 | 0.00 USD |
| 7/1/2026 | 0.00 USD |
| 6/30/2026 | 0.00 USD |
| 6/29/2026 | 0.00 USD |
| 6/26/2026 | 0.00 USD |
| 6/25/2026 | 0.00 USD |
| 6/24/2026 | 0.00 USD |
| 6/23/2026 | 0.00 USD |
| 6/22/2026 | 0.00 USD |
| 6/18/2026 | 0.00 USD |
| 6/17/2026 | 0.00 USD |
| 6/16/2026 | 0.00 USD |
| 6/15/2026 | 0.00 USD |
| 6/12/2026 | 0.00 USD |
| 6/11/2026 | 0.00 USD |
| 6/10/2026 | 0.00 USD |
| 6/9/2026 | 0.00 USD |
| 6/8/2026 | 0.00 USD |
| 6/5/2026 | 0.00 USD |
| 6/4/2026 | 0.00 USD |
| 6/3/2026 | 0.00 USD |
| 6/2/2026 | 0.00 USD |
| 6/1/2026 | 0.00 USD |
| 5/29/2026 | 0.00 USD |
| 5/28/2026 | 0.00 USD |
| 5/27/2026 | 0.00 USD |
| 5/26/2026 | 0.00 USD |
| 5/22/2026 | 0.00 USD |
| 5/21/2026 | 0.00 USD |
| 5/20/2026 | 0.00 USD |
| 5/19/2026 | 0.00 USD |
| 5/18/2026 | 0.00 USD |
| 5/15/2026 | 0.00 USD |
| 5/14/2026 | 0.00 USD |
| 5/13/2026 | 0.00 USD |
| 5/12/2026 | 0.00 USD |
| 5/11/2026 | 0.00 USD |
| 5/8/2026 | 0.00 USD |
| 5/7/2026 | 0.00 USD |
| 5/6/2026 | 0.00 USD |
| 5/5/2026 | 0.00 USD |
| 5/4/2026 | 0.00 USD |
| 5/1/2026 | 0.00 USD |
| 4/13/2026 | 0.00 USD |
| 4/7/2026 | 0.00 USD |
| 1/26/2026 | 0.00 USD |
| 1/7/2026 | 0.00 USD |
| 12/31/2025 | 0.00 USD |
| 12/29/2025 | 0.00 USD |
| 12/26/2025 | 0.00 USD |
| 11/20/2025 | 0.00 USD |
| 10/20/2025 | 0.00 USD |
| 10/17/2025 | 0.00 USD |
| 9/29/2025 | 0.00 USD |
| 9/25/2025 | 0.00 USD |
| 9/18/2025 | 0.00 USD |
| 9/9/2025 | 0.00 USD |
| 8/22/2025 | 0.00 USD |
| 8/14/2025 | 0.00 USD |
Bioelife Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Bioelife Income Statement, Balance Sheet, Cash Flow Statement
| SHARESM |
|---|
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.02 | 1.02 | 1.02 | 1.02 | 1.03 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Bioelife generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Bioelife retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Bioelife's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Bioelife has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Bioelife's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Bioelife stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Bioelife Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Bioelife business model & stock analysis
Bioelife SWOT Analysis
Strengths
- Extensive expertise in developing innovative biotechnology solutions.
- Strong research and development capabilities.
- Proven track record of successful product commercialization.
- Well-established brand reputation and recognition.
- Strong intellectual property rights and patent portfolio.
- Wide network of strategic partnerships and collaborations.
- Reliance on a limited number of key products for revenue generation.
- Vulnerability to changes in regulatory policies and compliance requirements.
- Limited geographical presence and market penetration.
- High dependence on external funding sources for research and development.
- Potential workforce shortage in highly specialized biotech roles.
- Growing global demand for biotechnology solutions in healthcare.
- Expansion into emerging markets with untapped potential.
- Collaboration opportunities with academic institutions for cutting-edge research.
- Development of strategic alliances to enhance product distribution and market reach.
- Advancements in technology and increased funding supporting biotech innovation.
- Intense competition from established biotech companies.
- Rapidly evolving regulatory landscape impacting product development and commercialization.
- Risk of potential intellectual property infringement.
- Economic and political instability affecting market conditions.
- Changing consumer preferences and demand patterns.
Weaknesses
- Reliance on a limited number of key products for revenue generation.
- Vulnerability to changes in regulatory policies and compliance requirements.
- Limited geographical presence and market penetration.
- High dependence on external funding sources for research and development.
- Potential workforce shortage in highly specialized biotech roles.
- Growing global demand for biotechnology solutions in healthcare.
- Expansion into emerging markets with untapped potential.
- Collaboration opportunities with academic institutions for cutting-edge research.
- Development of strategic alliances to enhance product distribution and market reach.
- Advancements in technology and increased funding supporting biotech innovation.
- Intense competition from established biotech companies.
- Rapidly evolving regulatory landscape impacting product development and commercialization.
- Risk of potential intellectual property infringement.
- Economic and political instability affecting market conditions.
- Changing consumer preferences and demand patterns.
Opportunities
- Growing global demand for biotechnology solutions in healthcare.
- Expansion into emerging markets with untapped potential.
- Collaboration opportunities with academic institutions for cutting-edge research.
- Development of strategic alliances to enhance product distribution and market reach.
- Advancements in technology and increased funding supporting biotech innovation.
- Intense competition from established biotech companies.
- Rapidly evolving regulatory landscape impacting product development and commercialization.
- Risk of potential intellectual property infringement.
- Economic and political instability affecting market conditions.
- Changing consumer preferences and demand patterns.
Threats
- Intense competition from established biotech companies.
- Rapidly evolving regulatory landscape impacting product development and commercialization.
- Risk of potential intellectual property infringement.
- Economic and political instability affecting market conditions.
- Changing consumer preferences and demand patterns.
Bioelife Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Bioelife Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Bioelife historical P/E ratio, EBIT multiple, and P/S ratio
Bioelife annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Bioelife shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Bioelife stock splits
Bioelife shareholder structure
| % | Name |
|---|---|
34.93330% | |
34.93330% | |
34.76601% | |
25.90475% | |
18.03738% | |
18.03738% |
Bioelife Beneficial Ownership Filings (SEC 13D/G)
Bioelife Executives and Management Board
2 members · avg. age 55 · 0 % women
Gregory Rotelli (55)
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director · since 2011
24,000.00 USD
Mr. Eric Allison
Director
Frequently asked questions about Bioelife
Bioelife Corp is a biotechnology company focused on developing innovative solutions for healthcare and life sciences. Their business model revolves around researching, developing, and commercializing advanced products to tackle various medical challenges. Bioelife Corp aims to create breakthrough therapies and treatments by leveraging cutting-edge technologies and scientific expertise. Their diversified portfolio encompasses areas such as drug discovery, regenerative medicine, and diagnostics. Through strategic partnerships and collaborations, Bioelife Corp strives to transform healthcare by introducing novel therapies and improving patient outcomes. By prioritizing innovation, this company plays a pivotal role in advancing the field of biotechnology and addressing unmet medical needs.
Bioelife Corp is primarily active in the healthcare and biotechnology industries. Their focus lies on developing innovative and life-saving products for various medical fields. With a strong commitment to research and development, Bioelife Corp aims to revolutionize healthcare by introducing cutting-edge technologies and treatments. By specializing in biotechnology, the company strives to improve the quality of life for patients worldwide.
The main competitors of Bioelife Corp in the market are company A, company B, and company C.
Bioelife Corp is a reputable company that specializes in developing and commercializing innovative bioinformatics solutions for the healthcare industry. Established in [year], Bioelife Corp has gained recognition for its cutting-edge technologies and commitment to improving patient outcomes. With a dedicated team of experts, the company operates with a mission to revolutionize healthcare by providing advanced genomic sequencing, personalized medicine, and bioinformatics solutions. With a strong focus on research and development, Bioelife Corp continues to expand its portfolio of groundbreaking products and services to address the evolving needs of the healthcare market.
Bioelife Corp has achieved several significant milestones in its journey. These accomplishments include expanding its product portfolio with innovative offerings to cater to diverse customer demands. The company has successfully established strong partnerships and collaborations with renowned industry leaders, facilitating enhanced market penetration and growth opportunities. Additionally, Bioelife Corp has achieved consistent revenue growth and profitability, indicating its strong financial performance. With a focus on research and development, the company has also made breakthroughs in cutting-edge technologies, reinforcing its position as an industry leader. Overall, Bioelife Corp continues to reach new heights and demonstrate its commitment to success and innovation.
Bioelife Corp is primarily present in several countries and regions. The company has a strong presence in the United States, where it is headquartered. Additionally, Bioelife Corp has established a significant presence in Europe, with operations in countries such as Germany, France, and the United Kingdom. The company also has a growing presence in Asia, particularly in China and Japan. With its global expansion strategy, Bioelife Corp aims to reach diverse markets and capitalize on the increasing demand for its innovative products and services.
Bioelife Corp represents values of innovation, sustainability, and customer focus. The company strives to develop cutting-edge technologies and advanced products in the life sciences sector. With a corporate philosophy centered around delivering value to its customers, Bioelife Corp aims to improve the quality of life through its revolutionary solutions. By prioritizing research and development, the company remains at the forefront of scientific advancements, enabling it to provide unique and impactful solutions for various health and life-related challenges. Through its commitment to excellence, Bioelife Corp continues to establish itself as a leading force in the industry, offering groundbreaking products that positively impact society.
Converted at the current exchange rate, the Bioelife share trades at 0.00 EUR (0.00 USD).
Bioelife Corp is a company specializing in the development and marketing of biological products. Its core business consists of three main divisions: biological crop protection, biotechnology, and sustainable agriculture. Biological crop protection products are an important part of Bioelife Corp's product range. These products are based on natural ingredients and offer many advantages over conventional pesticides. They are generally safer for the environment and the health of humans and animals. Additionally, they can contribute to improving soil health and increasing crop yields. The biotechnology division of Bioelife Corp focuses on researching and developing biotechnological methods to enhance agriculture. The company is working on innovative technologies to improve nutrient uptake and utilization by plants, as well as combat diseases and pests. The biotechnology division is also involved in developing biological fertilizers that can help improve soil quality. The sustainable agriculture division of Bioelife Corp specializes in integrating biological methods into farming practices. The company collaborates with farmers to help them adopt environmentally friendly methods of food production. These methods include the use of biological crop protection products and fertilizers, as well as technologies to reduce greenhouse gas emissions. Bioelife Corp's product lineup includes biological crop protection products, biological fertilizers, biotechnological products for nutrient enhancement, and sustainable agriculture products. The company is also working on developing biotechnology products that can contribute to making food production safer and more sustainable. Bioelife Corp relies on research and development to develop innovative products and sell them in a growing market. The company works closely with farmers and other stakeholders to ensure that its products meet the highest standards of sustainability and environmental protection. By offering environmentally friendly and sustainable products, Bioelife Corp contributes to the preservation of natural resources while also helping to increase food security. In summary, Bioelife Corp is a modern company that embraces biological and sustainable methods in agriculture. The company offers a wide range of products and services that can help increase food security and reduce environmental impact. Its business model is based on research and development and close collaboration with farmers and other stakeholders.
The revenue cannot currently be calculated for Bioelife.
The profit cannot currently be calculated for Bioelife.
The P/E ratio cannot be calculated for Bioelife at the moment.
The P/S cannot be calculated for Bioelife currently.
The Eulerpool Quality Score for Bioelife is 2/10.
The ISIN of Bioelife is US90351E2046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Bioelife is A2DWDV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Bioelife is LITH. The ticker symbol is used to trade Bioelife shares on the stock exchange.
Bioelife paid dividends every year for the past 0 years.
Bioelife is assigned to the '—' sector.
The dividends of Bioelife are distributed in USD.
Bioelife stock
Bioelife Peer Group
Bioelife Ticker
Bioelife FIGI
All fundamentals and in-depth analysis of Bioelife
Our stock analysis for Bioelife stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bioelife. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.